NCT04607200 2022-01-11
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
Agenus Inc.
Phase 2 Withdrawn
Clinical Trials
7 trialsNCT04001101 2021-11-30
Anti-PD-1 +/- RT for MSI-H Solid Tumors
University of Colorado, Denver
Phase 2 Withdrawn
NCT03945227 2020-10-19
Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)
Yonsei University
Phase 2 Withdrawn
NCT03775707 2019-05-06
Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria
Sun Yat-sen University
Phase 2 Withdrawn
NCT03803254 2019-05-06
HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT03782831 2019-05-02
TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT03746249 2019-04-17
Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn